OTC Switch Interest Cooled By Study Costs To Update Safety Data
This article was originally published in The Pink Sheet
Firms often are hesitant to prepare Rx-to-OTC switch applications because safety and efficacy data for their products are over a decade old, notes health care consultant Laura Mahecha.
You may also be interested in...
Perrigo Pegs Growth To Initiating OTC Switches, Not Following Brands' NDAs
"A foundation of this business has been," says Perrigo's Americas consumer business chief, Jeffrey Needham, "we are a fast follower. That's been our traditional model. We can't afford to do that going forward." In addition to initiating moving ingredients from Rx to OTC, firm is developing "national better brand" versions of drugs already available OTC.
FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap
CDER has been studying ideas such as pictograms to communicate instructions on administering opioid-reversal medication, but officials can’t predict when new approaches might help enable FDA to propose regulatory changes in the US switch process.
Petition Seeks OTC PPI Warning On Cancer Risk From Persistent Heartburn
OTC proton pump inhibitors should carry a warning that the products do not eliminate risks of esophageal cancer from persistent heartburn, says the Esophageal Cancer Action Network in a citizen petition to US FDA. FDA should “immediately” require the warning, which should be bold and prominent.